CHI, Philadelphia, PA
March 13 – 14, 2012
Pharmaceutical Companies are investing heavily into Indications Discovery. There is a tremendous commercial and medical value in Drug Repositioning, or Drug Repurposing i.e. finding a new indication for a drug. This presents an excellent strategy to achieve the optimal potential and thus maximize the value of a therapeutic drug. One of the bigger challenges is however, to connect the dots between currently approved drugs and new applications. Some of the issues which need to be addressed are how to deal with the increasing amount of data available from the interaction of these drugs in humans, how to deal with IP issues and how to translate new chemical and biological knowledge of these drugs into safe and effective novel therapeutics. Also, there is increasing demand for faster and less expensive ways of identifying potential hits. With the cost of bringing a new drug to market in the U.S. sometimes exceeding $1 billion by some estimates, this is a growing area of interest.
|
|